Expiration date: 04/2025
The composition and form of issue:
Solution for injections 0,5 % 1 ml contains:
Glutoxim 5 mg
in ampoules with ring or point of fracture in 1 or 2 ml in blistere 5 or 10 PCs. in cardboard pack 1 blister.
Solution for injection 1% 1 ml contains:
Glutoxim 10 mg
in ampoules with ring or point of fracture in 1 or 2 ml in blistere 5 or 10 PCs. in cardboard pack 1 blister.
Solution for injection 3 % in 1 ml contains:
Glutoxim 30 mg
in ampoules with ring or point of fracture in 1 or 2 ml in blistere 5 or 10 PCs. in cardboard pack 1 blister.
Feature:
Is representative tipitino — LS having a modulating effect on intracellular processes thiol metabolism, plays an important role in the regulation of genetic and metabolic processes in cells and tissues.
Pharmacological action:
Affects thiol-disulfide exchange and redox metabolism of cells, stimulates endogenous production of cytokines and hematopoietic factors, including interleukin 1, tumor necrosis factor, interferon, erythropoietin, reproduces the effects of interleukin-2 by induction of the expression of its receptors. Have a differentiated impact on normal (stimulation of proliferation and differentiation) and transformed (induction of apoptosis) cells. Stimulates bone marrow hematopoiesis (Erythro-, lympho-, granulocytopoiesis), activates phagocytosis, including immunodeficiency restores in the peripheral blood level of neutrophils, monocytes and lymphocytes, functional activity of tissue macrophages. Restores the natural anticancer and anti-infective immunity. The system has a cytoprotective effect.
Pharmacokinetics:
After the/m,/in, or subcutaneous injection, the bioavailability is greater than 90%. There is a linear relationship between dose and drug concentration in plasma. Cmax observed at/in the introduction within 2-5 min, when the/m for a period of 7-10 min, Metabolized in organs and tissues and excreted by the kidneys.
Indications:
Prevention and treatment of secondary immunodeficiency States associated with radiation, chemical and infectious factors, immuno - and myelosuppression, prolonged and chronic hepatitis (B and C) prevention of postoperative purulent complications to potentiation of therapeutic effect of antibiotics in chronic obstructive pulmonary disease.
In the complex of TB treatment of severe, common forms of tuberculosis of all localizations in the presence of drug resistance of Mycobacterium tuberculosis for the prevention of exacerbations of chronic hepatitis in patients with tuberculosis and the treatment of toxic complications of antituberculosis therapy.
In the combined therapy of moderate and severe psoriasis, including complicated erythroderma, arthropathy.
Contraindications:
Hypersensitivity, pregnancy, breast-feeding.
Application of pregnancy and breast-feeding:
Clinical studies of the drug during pregnancy and lactation have not been conducted.
Side effects:
Seldom — raising body temperature (up to 37,1–37,5 °C ), slight pain at the injection site.
Method of application and dose:
In/in, in/m, p/K. Daily 5-40 mg depending on the nature of the disease (1 course — 50-300 mg). In the treatment of chronic respiratory diseases, diseases of the genitourinary system atopic allergies course duration — 2-3 weeks. In the complex therapy of tuberculosis for 60 mg/day (30 mg 2 times a day) daily for 2 months. After the transition, the specific inflammation in the productive phase appoint/m 10-20 mg 1-2 times a day (morning and evening) 3 times a week. Repeated courses if necessary after 1-6 months.
Psoriasis daily, 10 mg/day for 15 days, then another 10 injections 2 times per week/m in non-complicated forms of psoriasis — 10 ml/day for 10 days.
Prophylactic: 5 to 10 mg daily.
Special instructions:
As a solution carrier for intravenous use isotonic solution of sodium chloride or 5% glucose solution.
